10-Q: NeuroPace Q3 2025: Revenue Soars 30%, Net Loss Narrows

NeuroPace, Inc. reported robust 30% revenue growth and a significant 36% reduction in net loss for Q3 2025, driven by strong RNS System sales and improved gross margins.

Summary

• Revenue for the three months ended September 30, 2025, increased by 30% to $27.4 million, up from $21.1 million in the prior year period.
• Net loss for the three months ended September 30, 2025, significantly narrowed by 36% to $3.5 million, compared to $5.5 million in the prior year period.
• Gross profit increased by 37% to $21.2 million for the quarter, with gross margin improving to 77.4% from 73.2%.
• For the nine months ended September 30, 2025, revenue grew 26% to $73.4 million, and net loss decreased 14% to $18.7 million.
• The company completed a follow-on offering in February 2025, raising $69.7 million in net proceeds, using $49.5 million to repurchase shares from KCK Ltd.
• A new $60.0 million MidCap Term Loan was secured in June 2025, used to repay the previous CRG Term Loan of $61.9 million, resulting in a $0.5 million loss on debt extinguishment.
• The exclusive distribution agreement with DIXI Medical USA Corp. expired on September 30, 2025, with a six-month wind-down period for inventory sales.
• Preliminary one-year results from the NAUTILUS study for generalized epilepsy met the primary safety endpoint but did not reach statistical significance for the primary effectiveness endpoint in the overall study.

Sentiment

Score: 7

Explanation: The company demonstrated strong revenue growth and significant improvement in net loss and gross margin, indicating positive operational momentum. It also secured new, more favorable debt financing and is actively pursuing label expansion. However, it remains unprofitable, faces the loss of DIXI Medical revenue, and the NAUTILUS study's primary effectiveness endpoint was not met, which introduces some uncertainty for future growth.

Positives

• Revenue increased by 30% to $27.4 million for the three months ended September 30, 2025, and by 26% to $73.4 million for the nine months, driven by increased RNS System unit sales and service revenue.
• Net loss significantly narrowed by 36% to $3.5 million for the three months and by 14% to $18.7 million for the nine months, indicating improved financial performance.
• Gross margin improved to 77.4% for the quarter (from 73.2%) and 77.2% for the nine months (from 73.4%), primarily due to lower fixed costs per unit from increased RNS System production volume.
• Operating loss improved by 39% for the three months and 19% for the nine months, reflecting better operational efficiency relative to revenue growth.
• Secured a new $60.0 million MidCap Term Loan, providing stable long-term financing until June 2030, and repaid the higher-interest CRG Term Loan.
• Cash, cash equivalents, and short-term investments increased to $60.0 million as of September 30, 2025, from $52.8 million at December 31, 2024.
• The NAUTILUS study for generalized epilepsy met its primary safety endpoint, confirming the RNS System's favorable safety profile.
• Post-approval study data for the RNS System showed strong efficacy, with an 82.0% median seizure reduction at 36 months and 22% of patients seizure-free for at least one year.
• Expansion of commercial efforts to target epileptologists and functional neurosurgeons outside of Level 4 CECs, following FDA approval of updated qualification criteria.

Negatives

• Continued to incur net losses, with an accumulated deficit of $549.7 million as of September 30, 2025.
• Operating expenses increased across all categories for both the three and nine-month periods, with sales and marketing up 27% and 20% respectively, and R&D up 14% and 19%.
• The primary effectiveness endpoint of the NAUTILUS study for generalized epilepsy did not reach statistical significance in the overall study population.
• The exclusive distribution agreement with DIXI Medical USA Corp. expired on September 30, 2025, which will lead to a loss of associated revenue after the wind-down period.
• Incurred a $0.5 million loss on debt extinguishment related to the repayment of the CRG Term Loan.
• Interest income decreased by 12% for the three months and 7% for the nine months due to lower interest yields.
• Other income (expense), net, decreased significantly by $0.9 million for the nine months, primarily due to the debt extinguishment loss and lower unrealized gains on short-term investments.

Risks

• Reliance on the RNS System as the primary revenue source, currently limited to adults with drug-resistant focal epilepsy in the U.S.
• Commercial success depends on significant market acceptance and increasing the number of patients treated, both within Level 4 CECs and in the community setting.
• Dependence on a limited number of single-source suppliers for critical components, making the company vulnerable to supply shortages and price fluctuations.
• Inability to accurately forecast customer demand for products, potentially leading to inventory write-downs or unmet demand.
• Intense competition from other treatment options for drug-resistant focal epilepsy, including ablative/resective surgery and other neuromodulation devices (VNS, DBS).
• Potential for inadequate or unfavorable changes in reimbursement for RNS System implant procedures and ongoing patient care.
• Requirement for appropriate neurosurgeon and epileptologist training for RNS System implantation and programming, with inadequate training potentially leading to negative patient outcomes.
• Failure to obtain expanded FDA labeling for generalized epilepsy and pediatric patients could harm growth potential.
• Recent changes in FDA staffing levels and potential government shutdowns could delay review of regulatory submissions for indication expansion.
• Pervasive and continuing FDA regulatory requirements, with non-compliance potentially leading to enforcement actions, product recalls, or operational restrictions.
• Risks related to data privacy and security laws (e.g., HIPAA, CCPA, GDPR), including the use of AI/ML technologies, which could lead to significant costs, liabilities, and reputational harm.
• History of net losses and expectation to continue incurring losses for the foreseeable future, with no guarantee of sustained profitability.
• The MidCap Term Loan contains restrictive covenants and financial maintenance covenants, and non-compliance could lead to an event of default and immediate repayment demands.
• Expiration of the exclusive distribution agreement with DIXI Medical will result in a loss of associated revenue, potentially impacting revenue growth and the ability to achieve cash flow breakeven.
• Unstable market and economic conditions, including inflation and interest rate changes, may have serious adverse consequences.
• Potential for product liability lawsuits, which could incur substantial liabilities and require limiting or halting product sales.
• Intellectual property risks, including challenges to patents, inability to obtain necessary licenses, and limitations of foreign intellectual property protection.

Future Outlook

The company expects to continue incurring net losses and negative cash flows in the near term due to significant investments in research and development and commercial activities. Management believes existing cash, cash equivalents, and short-term investments of $60.0 million will fund operations for at least the next 12 months. The company plans to file an expanded label submission to the FDA for generalized epilepsy prior to the end of 2025 and expects its collaboration with Rapport Therapeutics to continue through the first half of 2028. Efforts to expand the sales force and market reach beyond Level 4 epilepsy centers are ongoing.

Management Comments

• "Management believes that the Company's cash, cash equivalents and short-term investments will allow the Company to continue its planned operations for at least the next 12 months from the date of the issuance of these unaudited interim condensed financial statements."
• "We intend to continue making significant investments in research and development, clinical studies and regulatory affairs to support ongoing and future regulatory submissions for retaining and expanding indications of our RNS System, including to patients with drug-resistant generalized epilepsy and patients under the age of 18, support continuous improvements to our RNS System, and develop future products that address neurological disorders."
• "We have also made significant investments in building our field commercial team and intend to make significant investments in sales and marketing efforts in the future, including initiatives to drive awareness and expand our referral channel to increase the number of drug-resistant epilepsy patients referred to CECs."
• "There are no changes in the Company's plan to file the expanded label submission to the FDA prior to the end of 2025."
• "While we continue to believe that we have the ability to achieve cash flow breakeven on our expected timeline without revenue from the distribution agreement, our revenue growth, financial condition and results of operations may be materially affected, including our ability to achieve cash flow breakeven and our expected long-range revenue growth."

Industry Context

NeuroPace operates in the competitive medical device industry, specializing in brain-responsive neuromodulation for drug-resistant epilepsy. Its RNS System competes with other neuromodulation devices like LivaNova's VNS System and Medtronic's DBS System, as well as traditional surgical options. The company is expanding its commercial strategy to reach epileptologists and neurosurgeons outside of Level 4 comprehensive epilepsy centers, aiming to broaden market adoption. It is also leveraging its unique brain activity data and developing AI-enabled software tools to optimize treatment and potentially address other neurological disorders, positioning itself at the forefront of personalized epilepsy care amidst evolving regulatory and technological landscapes.

Comparison to Industry Standards

• The filing does not provide specific global benchmarks or direct comparisons to named comparable companies or projects in terms of financial performance or product results beyond mentioning competitors like LivaNova plc (VNS System) and Medtronic plc (DBS System).
• The company highlights the RNS System's unique brain-responsive neuromodulation and continuous brain activity data recording capabilities as differentiated features compared to alternative neuromodulation devices.

Legal Proceedings

• Not involved in any pending legal proceedings that are believed to have a material adverse effect on the business, results of operations, financial condition, or cash flows.

Related Party Transactions

• Repurchased 5,270,845 shares of common stock from KCK Ltd., a significant stockholder, for $49.5 million in February 2025.

Stakeholder Impact

• Shareholders: Potential for dilution from future equity raises, stock price volatility, and influence of principal stockholders on corporate decisions.
• Employees: Stock-based compensation plans, potential for increased headcount and responsibilities due to growth, but also risks related to retention and competition for skilled personnel.
• Customers (Healthcare Providers/Hospitals): Continued availability of RNS System, training requirements, and impact of reimbursement policies on their ability to use the product.
• Patients: Access to RNS System for drug-resistant epilepsy, potential for expanded indications, and importance of positive clinical outcomes and proper device usage.
• Creditors: Subject to covenants and repayment obligations under the MidCap Term Loan, with potential for default if covenants are not met.
• Suppliers: Dependence on limited and single-source suppliers creates risks for supply chain disruptions and price fluctuations.

Next Steps

• File expanded label submission to the FDA for generalized epilepsy prior to the end of 2025.
• Continue patient participation in the NAUTILUS study through two years after device implant.
• Continue collaboration with NEST and the FDA to pursue the use of real-world data for the RESPONSE study (pediatric focal epilepsy).
• Expand commercial efforts and sales force to target centers and clinicians outside of Level 4 CECs.
• Continue investing in research and development for existing products, new products, and expanded indications.
• Wind-down sales of DIXI Medical products until the end of Q1 2026.

Key Dates

Recommendation

While NeuroPace shows strong revenue growth and improved financial performance, narrowing its net loss and improving gross margins, it remains unprofitable with a significant accumulated deficit. The termination of the DIXI Medical agreement introduces a future revenue headwind, and the NAUTILUS study's primary effectiveness endpoint not meeting statistical significance adds uncertainty to its label expansion strategy. The company has secured new financing, which is positive for liquidity, but it operates in a highly competitive and regulated environment with inherent risks related to market acceptance, supply chain, and intellectual property. The current performance indicates progress, but significant investments are still required for future growth and profitability, warranting a "hold" as investors await further clarity on label expansion and sustained profitability.

Keywords

Medical device, Epilepsy, Neuromodulation, RNS System, FDA, Financial results, Q3, NeuroPace, Drug-resistant epilepsy, Brain-responsive neuromodulation